Biotechnology News and Research

RSS

Neurologix hires MTS Health Partners, L.P. as strategic advisor to augment business development activities

Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced that it has hired MTS Health Partners, L.P. as strategic advisor to complement and augment the company’s ongoing business development activities.

12 Feb 2010

ISMPP announces opening of registration for 6th annual meeting on medical publications

The International Society for Medical Publication Professionals (ISMPP) is pleased to announce the opening of registration for its 6th annual meeting, "Delivering Value and Driving Advocacy in Medical Publications." The meeting will run from April 19 to 21, 2010, in Arlington, VA, at the Crystal Gateway Marriott.

12 Feb 2010

World leaders need to alter their notions on sustainable agriculture to prevent starvation catastrophe

Yields from some of the most important crops begin to decline sharply when average temperatures exceed about 30 degrees Celsius, or 86 Fahrenheit. Projections are that by the end of this century much of the tropics and subtropics will regularly see growing season temperatures above that level, hotter than the hottest summers now on record.

12 Feb 2010

Better and standardized animal models needed for musculoskeletal regenerative medicine

Clinical testing and development of novel therapies based on advances in tissue engineering and regenerative medicine that will one day enable the repair and replacement of diseased or damaged human muscle, bone, tendons, and ligaments depends on the availability of good animal models.

12 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

pSivida Corp. , a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today announced financial results for its second quarter and six months ended December 31, 2009.

12 Feb 2010

Therapeutic cell types obtained from iPS cells demonstrate abnormal expansion and early cellular aging

Advanced Cell Technology, Inc. or “ACT” reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging. The research, which appears online (published-ahead-of- print) in the journal STEM CELLS by ACT and its collaborators at Stem International (SCRMI), Harvard Medical School, and the University of Illinois, compares a variety of replacement cell types derived from human iPS cells with their embryonic stem (ES) cell counterparts. The findings support the use of ACT’s single blastomere-derived human embryonic stem cell lines which do not display early aging.

12 Feb 2010

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."

12 Feb 2010

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.

12 Feb 2010

Corey McPherson Nash, Biogen Idec team up to create new website for life science community

Corey McPherson Nash (www.corey.com), a leading national branding and design firm, recently partnered with Biogen Idec to create a new Web site design for the life sciences company.

12 Feb 2010

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).

11 Feb 2010

RadPharm and Medifacts International announce merger

RadPharm Inc., a leading Imaging Core Laboratory, and Medifacts International, Inc., a leading Cardiovascular Core Laboratory, today announced the merger of their business operations. The combined company will be named CoreLab Partners ("CoreLabs") and will have its corporate headquarters in Princeton, New Jersey.

11 Feb 2010

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

QIAGEN N.V. and Celera Corporation today announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN’s ResPlex II assay for detection of respiratory pathogens.

From QIAGEN Manchester Limited 11 Feb 2010

PAREXEL International, Proteome Sciences form biomarker alliance

PAREXEL International Corporation, a leading global biopharmaceutical services provider, and Proteome Sciences plc, a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of an alliance focused on enhancing PAREXEL's biomarker capabilities for early phase clinical development. PAREXEL is using Proteome Sciences' PS Biomarker Services™ protein and peptide biomarker capabilities to support biopharmaceutical companies in making earlier assessments of new compounds in development.

From Parexel 11 Feb 2010

SafeBridge Consultants validates improved hygiene air sampling and analytical method for naproxen sodium

SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.

11 Feb 2010

Role of evidence-based pathways in providing high quality, cost effective oncology care

Although health care reform is taking a back seat to the economy on Capitol Hill, discussions continue in the health care industry on how best to lower the cost of care while maintaining or improving patient outcomes.

11 Feb 2010

Therapeutic cell types obtained from iPS cells exhibit abnormal expansion and early cellular aging

Advanced Cell Technology, Inc. reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging.

11 Feb 2010

Allos Therapeutics' disease-specific registry for patients with PTCL enrolls first study participant

MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, is pleased to announce that Allos Therapeutics' new international disease-specific registry for patients with peripheral T-cell lymphoma (PTCL) has enrolled its first study participant.

11 Feb 2010

PwC: Companies in Life Sciences sector captured largest share of overall venture capital during 2009

Companies in the Life Sciences sector, which includes the biotechnology and medical device industries, captured the largest share of overall venture capital during 2009, reflecting the relative strength of the sector during the economic downturn, according to PricewaterhouseCoopers LLP (PwC).

11 Feb 2010

Biotechnology News and Research

Neurologix hires MTS Health Partners, L.P. as strategic advisor to augment business development activities

ISMPP announces opening of registration for 6th annual meeting on medical publications

World leaders need to alter their notions on sustainable agriculture to prevent starvation catastrophe

Better and standardized animal models needed for musculoskeletal regenerative medicine

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Second-quarter fiscal 2010 results announced by Pharmacyclics

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

Therapeutic cell types obtained from iPS cells demonstrate abnormal expansion and early cellular aging

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

Corey McPherson Nash, Biogen Idec team up to create new website for life science community

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

RadPharm and Medifacts International announce merger

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

PAREXEL International, Proteome Sciences form biomarker alliance

SafeBridge Consultants validates improved hygiene air sampling and analytical method for naproxen sodium

Role of evidence-based pathways in providing high quality, cost effective oncology care

Therapeutic cell types obtained from iPS cells exhibit abnormal expansion and early cellular aging

Allos Therapeutics' disease-specific registry for patients with PTCL enrolls first study participant

PwC: Companies in Life Sciences sector captured largest share of overall venture capital during 2009

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News